The UK's much-vaunted 100,000 genomes project is a ground-breaking initiative, but significant obstacles remain before it can have an impact on patient care, according to experts.Life Sciences Minister George Freeman... Read more
Stratified medicine collaborations in the UK are set to benefit from a further £13.7 million cash injection from the Medical Research Council (MRC) to investigate cancer, heart disease, asthma and... Read more
Due to popular demand The Creative Floor Healthcare Awards are back for their second year.
And will continue to be the only healthcare award show on earth that will donate a percentage of profits to help young talent break into the health and wellness creative industry. Last year raised £7k and the winners of the 2014 awards decided that the profits would go to The School of Communications Arts 2.0.
This year brings a few more surprises. Two more categories have been added: Best Healthcare Company and Best Communications Agency.
As well as lining up the best Creative Directors from health and wellness agencies from across the globe they also have bought in Group Creative Director of Apple, the Global Creative Director of Unilever and the world’s most awarded art director, the legendary Paul Belford.
You can see the full list of judges here:
·Ben Kay, Group Creative Director Apple, Media Arts San Francisco
·Tony Hardcastle, Global Creative Director Unilever, DLKW Lowe
·Paul Belford, Executive Creative Director, Paul Belford Ltd.
·Daryl Corps, Creative Director, Droga5, Sydney
·Simon Rice, Creative Director, AMV BBDO
·Jeremy Perrott, Global Creative Director, McCann Healthcare
·Jac Nolan, Executive Creative Director, Digitas Health
·Dennis Field, Group Creative Director, Langland,
·Dominic Marchant, Founder, DJM
·Elizabeth Elfenbein, Co-Chief Creative Officer, The Cement Bloc New York
·Rich Levy, Chief Creative Officer, Draft FCB Health
·Hugh Fitzhardinge, Creative Director, Ward6
Shaheed Peera, Founder and CEO said: “The calibre of judges this year is greater than anything I’ve ever seen at any other health and wellness award show. It’s going to feel pretty special to win something here.”
Sponsors of the awards are Advertising Health, pharmaphorum, Young Creative Council, School of Communication Arts 2.0 and The Ideas Foundation.
THE EARLY BIRD DEADLINE IS 27 FEBRUARY AND FINAL DEADLINE FOR ALL ENTRIES IS 27 MARCH.
The Creative Floor was founded in 2009 by Shaheed Peera. Shaheed is also currently the Executive Creative Director at Publicis Life Brands Resolute (http://plbr.com). And created the site as a gift to the advertising industry. Its aim was to help connect creatives portfolios with the advertising industry. Unlike other portfolio sites, it’s exclusively for advertising creatives who work (or want to work) within the creative departments of ad agencies. Creative Directors and agencies can now cherry pick at their convenience, the best talent the world has to offer 24/7, without the expense or hassle of recruiters.
The Creative Floor has sponsored various free talks to students and has partnerships with The School of Communication Arts 2.0. The Ideas Foundation, Young Creative Council, Single Creatives, Nabs and Central St. Martins.
To visit the site please go to: http://thecreativefloor.com
Veeva Systems and BMI SYSTEM Partner to Deliver Complete EFPIA Compliance Management Solution
The life sciences industry continues to face increasingly stringent compliance and disclosure regulations and is looking at ways to meet these demands at a global, regional, and local level. 2015 marks the start of a new era in Europe as starting this year, life sciences companies will have to record all payments and 'transfers of value' to healthcare professionals and healthcare organisations, and make this data publicly available in 2016. However, burdened with multiple systems for managing customer data has meant that companies have struggled to streamline payment-tracking processes and deliver accurate reporting.
Veeva Systems and BMI SYSTEM today announced their partnership to deliver a cloud-based solution that enables life sciences companies to manage complex EFPIA regulations ahead of the 2016 deadline. The combined Veeva Network customer master and BMI SYSTEM NAYA transparency solution dramatically simplifies the tracking and capture of HCP and HCO expenditure data across multiple source systems and countries. It also provides the flexibility required to fully comply with the EFPIA guidelines and local market regulations for each of the 33 countries in the initiative.
BMI has joined the Veeva Network Partner Program and Veeva Network is now BMI’s preferred customer master solution. Integration of BMI SYSTEM’s NAYA compliance solution and Veeva Network enables unprecedented accuracy of spend reporting and compliance with new EFPIA payment disclosure requirements.
Read the full press release below:
Veeva Systems and BMI SYSTEM Partner to Deliver Complete EFPIA Compliance Management Solution
BMI SYSTEM becomes preferred Veeva Network partner for spend transparency; BMI SYSTEM selects Veeva Network as preferred customer master solution
BARCELONA, SPAIN and PARIS, FRANCE — 8 Jan, 2015 — Veeva Systems and BMI SYSTEM today announced BMI SYSTEM joins the Veeva Network Partner Program. The companies also announced Veeva Network is now BMI SYSTEM’s preferred customer master solution. The integrated BMI SYSTEM’s NAYA Transparency solution and Veeva Network Customer Master software enables unprecedented accuracy of spend reporting and compliance with new European Federation of Pharmaceutical Industries and Associations (EFPIA) payment disclosure requirements.
Burdened with multiple systems for managing customer data, life sciences companies have struggled to streamline payment-tracking processes and deliver accurate reporting. Today, facing increasingly stringent compliance and disclosure regulations, the industry is seeking efficient ways to meet these demands at a global, regional, and local level. In Europe, EFPIA has mandated companies publically disclose the monetary value of most payments – including financial sponsorship and other significant direct and indirect support – made to local healthcare professionals (HCPs) and healthcare organisations (HCOs) by January 2016.
Veeva Network Customer Master software and BMI SYSTEM’s NAYA Transparency solution dramatically simplify the tracking and capture of large, complex volumes of HCP and HCO expenditure data across multiple source systems and countries, with every individual recipient uniquely identified to avoid data duplication. It provides the flexibility required to fully comply with EFPIA guidelines and local market regulations for each of the 33 countries in the initiative, many of which have differing reporting requirements. In addition, it centralises and manages compliance-related information for every covered recipient. Transparency HCP related data attributes are captured by NAYA and seamlessly integrated into Veeva Network, enabling better HCP engagement by customer-facing teams and faster information audit and monitoring when required.
“The new EFPIA transparency code has significant consequences for life sciences,” said Dr. Peter Dieners, a leading healthcare industry compliance lawyer at Clifford Chance, recently in Corporate Compliance Zeitschrift magazine. “Strong data governance capabilities are needed in order to enable the collection, storage, and publishing of relevant data as and when required.” Technology that automates and speeds the management of this information will help avoid the risk of non-compliance.
“The need for transparency within the pharmaceutical industry has never been greater, especially with the fast-approaching EFPIA deadline,” said Guillaume Roussel, director of strategy for Veeva Network in Europe. “A solution that allows organisations to manage diverse data sources more effectively for a single view of customer spend is essential to not only meet regulatory requirements, but also to maintain business integrity and public trust.”
Traditional customer data management systems have typically utilised cumbersome and highly manual processes, which can take weeks to compile the relevant information. Veeva Network’s cloud architecture enables real-time data verification and update, ensuring fast, accurate spend capture and reporting right down to the individual level.
The Veeva Network Customer Master solution uniquely identifies every covered recipient and centralises HCP-related compliance information. BMI SYSTEM’s NAYA solution provides a spend data repository and reporting engine to enable the spend publication based on local disclosure requirements. The integration between the two solutions allows for seamless exchange of information to ensure accurate and consistent spend transparency.
“A complete, clean customer master is the prerequisite for accurate spend reporting, but it’s often the missing part of the equation,” added Roussel. “Bringing Veeva Network customer master together with BMI SYSTEM’s NAYA solution together greatly accelerates our customers’ ability to meet EFPIA requirements through seamless implementation, saving them developing costly and laborious custom-built systems.”
“Veeva Network and NAYA finally allow life sciences to effectively track, manage, and report large volumes of data across channels and markets – with a single, accurate repository of spend data in the cloud,” said Francis Geysermans, co-founder of BMI SYSTEM. “As regulations evolve, the agility and flexibility delivered by cloud technology will be key to adapting quickly to market and compliance changes.”
About BMI SYSTEM
BMI SYSTEM is a software design company dedicated to transparency, regulatory compliance and process optimisation for pharmaceutical, medical device and cosmetics industries. With its NAYA software suite, BMI SYSTEM supports more than 50 clients across 30 countries in their compliance of local and global regulations across Europe and North America. For more information, visit www.bmi-system.com.
About Veeva Network and Veeva Commercial Cloud
The Veeva Network line of customer master solutions offers life sciences-specific data, software, and stewardship services. Through Veeva Network, life sciences companies can gain direct access to millions of accurate customer profiles generated from authoritative industry sources worldwide. Veeva’s data stewards verify all information, rigorously safeguarding data integrity. And Veeva Network’s customer master application gives companies a single, global data model for multi-country master data management.
Veeva Network is part of Veeva Commercial Cloud, a unified set of applications that marries multichannel interactions, customer data, and compliant content. With Veeva CRM, Veeva Network customer master, and Veeva Vault for regulated content management interoperating seamlessly in the cloud, companies can deliver a fully orchestrated, personalised customer experience across all channels while ensuring compliance. Companies have seamless access to multichannel sales and marketing, targeting, reference, and compliance data all in Veeva Commercial Cloud.
About Veeva Systems Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 200 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices in Europe, Asia, and Latin America. For more information, visit www.veeva.com.
This release contains forward-looking statements, including statements regarding benefits from the use of Veeva’s solutions and general business conditions. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended October 31, 2014, which is available on the company’s website at www.veeva.com under the Investors section and on the SEC’s website at www.sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
Is KAM a new word describing old selling habits or can this be a future business model for Pharma?
Definitions are rare and many people understand many different things when using or hearing the acronym KAM. The first textbook about KAM in Pharma is available. It clarifies many details like the acronym itself. Interestingly enough the understanding of KAM is at least volatile: What is an account? How would you decide which account is key and who manages what in KAM? These are questions hardly ever answered or clarified. This first ever textbook on Pharma Key Account Management is meant to provide a basis for discussion between professionals. It will perfectly help to expand the view beyond one's own nose.
KAM in Pharma 3.0 is now available at Amazon and other bookstores.
About the author: 40 years ago, Hanno Wolfram has started to work in the pharmaceutical industry. Being self-employed since 18 years allowed him to learn a lot in consulting and change projects in more than 25 countries.
The attempt to share expertise and clarify vital details, was the basis writing about Key Account Management in Pharma. The previously written German textbook about "Pharma Key Account Management" now finds its expansion and upgrading in a fully new English and internationally valid version. It carries relevance for many markets and examples from Europe, China, India and many other places. The book will enrich the discussion of professionals.
Apps & Digital Resources vie for top honour at eyeforpharma Barcelona Awards
Two thirds of the finalists for the ‘Most Valuable Patient Initiative’ in the 2015 eyeforpharma Barcelona Awards have used interactive digital resources or mobile applications to engage with the patient; a tell-tale sign of the dominance of patient engagement as a focus for pharma right now. The list of finalists, announced today, includes Abbvie, AstraZeneca, Bayer, Janssen Healthcare Innovation and Novartis all vying for the ultimate accolade in pharma; to be crowned ‘most valuable’ to their patients.
Projects from Abbvie, in partnership with communications agency Biosector2 and Janssen Healthcare Innovation, in conjunction with DePuy Synthes and the orthopaedic department of Guy’s & St Thomas’ Hospital in London, are based around interactive websites which empower patients to take control of their health and be educated and supported throughout their relevant treatment, while Bayer Healthcare Turkey stands out with their Women’s Health TV, developed by 2014 category winner Pelin Icil, which addresses the issue of poor communication between women and their gynaecologists in Turkey.
The judges, who include patient representatives Heidi Floyd and Jack Whelan as well as senior pharmaceutical executives Alberto Grua, Chief Commercial Officer EU, Australia and North-America and member of the Corporate Executive Board of Grünenthal and John Pugh, Head of Digital Innovation at Boehringer Ingelheim favoured projects which could demonstrate real patient-experience improvement and those which showed a real understanding of culture and patient-need.
Of Janssen Healthcare Innovation’s Care4Today all-encompassing initiative, which combines an interactive patient website and a printed educational pack for hip & knee replacement patient the judges were unanimously impressed. Patient-judge Heidi Floyd commented: “Guiding a patient from beginning to end of their surgical journey, stepping through all the way to end of recovery; magnificent. As patients, we often are overwhelmed and unable to absorb required data while preparing for life-changing surgery. This resource appears to be the perfect tool to allow and encourage patients to educate themselves about the intense process at their own pace. Health information such as this will change the future for patients and caregivers worldwide.”
Winners will be announced at the 2nd annual eyeforpharma Barcelona Awards, on Tuesday 24th March 2015 at the CCIB, Barcelona from 7.30pm, as part of the largest gathering of pharma executives, eyeforpharma Barcelona. The evening will be attended by the top 200 VIPs from the pharma industry.
The Drug Launch Officer’s Handbook: How to Master New Drug Launches
Sometimes it is easier to fail than to pull through and succeed. As much as this sounds discouraging, it could actually serve as a sign for the drug industry, that a shift of approach is needed when it comes to establishing the guidelines for a successful drug launch. Indeed, this should be a call for a change of attitudes towards a data-driven approach to the current brutal competition between new drugs on the market.
Understanding Current Challenges
In order to better understand the challenges and difficulties involved in managing a successful drug launch, pharmaceutical companies not only have to be aware and informed of current trends, but really master the drug launch as a unique and dedicated area of expertise.
Adopting New Hybrid Strategies
That’s why it is crucial to educate ourselves with the latest practices and techniques available to make a product stand out from its competitors. A single strategy no longer suffices in giving your product the advantage it needs; you have to obtain a cross-disciplinary approach to bring efforts from different departments together, creating a dedicated factory to be producing only that- drug launches.
Verix Makes You an Expert
For these purposes, Verix has developed a step-by-step “tutorial” to help you become an expert in drug launches, giving you that edge to make your product stand out: Know your product; know your customers; get familiar with more launch types other than blockbuster; learn how to leverage your data into marketing flexibilities; build your own little “launch factory”, and so much more.
Don’t Miss Out
Don’t just aim to keep your head above water in the competitive drug industry today- aspire to become an expert in drug launch, and ensure a secure pull-through of your product, with Verix’s newly released ebook “Data & Creativity: A Complete Guide to Mastering Drug Launches“.